Oncolytic viruses: emerging options for the treatment of breast cancer

  title={Oncolytic viruses: emerging options for the treatment of breast cancer},
  author={Yogesh Ravindra Suryawanshi and Tiantian Zhang and Karim Essani},
  journal={Medical Oncology},
Breast cancer (BC) is the most common type of cancer among women and is the second most common cause of cancer-related deaths, following lung cancer. Severe toxicity associated with a long-term use of BC chemo- and radiotherapy makes it essential to look for newer therapeutics. Additionally, molecular heterogeneity at both intratumoral and intertumoral levels among BC subtypes is known to result in a differential response to standard therapeutics. Oncolytic viruses (OVs) have emerged as one of… 

Chemovirotherapeutic Treatment Using Camptothecin Enhances Oncolytic Measles Virus-Mediated Killing of Breast Cancer Cells

The results demonstrated that co-treatment of MV with CPT yielded enhanced cytotoxicity against breast cancer cells and demonstrated the potential value of MV plus CPT as a novel chemovirotherapeutic treatment against Breast cancer and as a strategy to enhance MV oncolytic activity.

Immuno-Oncolytic Virotherapy for Melanoma

This chapter includes an overview of the history of and making of OVs as well as a detailed summary of current clinical trials in melanoma patients.

Perspectives on immunotherapy via oncolytic viruses

Open issues, on the most promising lines of research in the OV field and, more in general, on how OVs could be improved to achieve real clinical breakthroughs in cancers that are usually difficult to treat by immunotherapy are focused on.

Oncolytic Viruses for Malignant Glioma: On the Verge of Success?

The obstacles faced by oncolytic viruses in malignant glioma patients are discussed and strategies that are being used to overcome these limitations to optimize delivery and trigger inflammatory immune responses in and around tumors are discussed.

Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology

The identification of individual PG profile should be a new resource for oncologists to make treatment decisions for the patients to minimize the toxicity and or inefficacy of therapy, to allow the clinicians to evaluate benefits and restrictions, regarding costs and applicability, of the most suitable pharmacological approach for performing a tailor-made therapy.

The Therapeutic Potential of Targeting Tumor Microenvironment in Breast Cancer: Rational Strategies and Recent Progress

These observations provide a proof of concept of targeting TME compartments as a novel potential therapeutic approach in treatment of this malignancy, which is the main interested for current review.

Photodynamic Therapy, a Potential Therapy for Improve Cancer Management

Photodynamic therapy (PDT) has shown great potential in treating breast cancer and even greater therapeutic outcomes can be obtained when combining PDT with other therapies such as immunotherapy or nanomedicine.

Oncolytic Tanapoxvirus for Melanoma Therapy

It is demonstrated that IL-2 inhibits virus replication through intracellular components and without activating the interferon-signaling pathway, providing compelling evidence that 15L and/or 66R gene were deleted and that these viruses were generated as a result of double crossover recombination events during transfection and infection.

T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors

TPV recombinants expressing mCCL2 and mIL-2 showed a significant therapeutic effect in MDA-MB-231 tumor xenografts, in nude mice through induction of potent antitumor immune responses, and merit further investigation as alternative treatment options for human breast cancer.

Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy

These studies provide a mechanistic base for a novel anti-cancer regimen composed of an OAd in combination with palbociclib for the treatment of ER+ breast cancer.



Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer

Preliminary data supports continuing the clinical development of oncolytic adenoviruses for treatment of breast cancer, including TNBC, as promising efficacy in preclinical studies and possible antitumor activity in breast cancer patients refractory to other forms of therapy are supported.

Promising oncolytic agents for metastatic breast cancer treatment

In order for the promise of oncolytic virotherapy to be fully realized for breast cancer patients, effectiveness must be demonstrated in metastatic disease.

Oncolytic virotherapy of breast cancer.

Targeted Therapies for Brain Metastases from Breast Cancer

  • V. VenurJ. Leone
  • Biology, Medicine
    International journal of molecular sciences
  • 2016
The common targetable pathways in the management of breast cancer patients with brain metastases are reviewed, and the current state of the clinical development of drugs against these pathways is reviewed.

Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy

By monitoring VSV replication at the tumor site and maximizing 5FC bioavailability, the treatment regimen was optimized and improved survival of animals bearing TSA mammary adenocarcinoma, demonstrating the necessity of optimizing each step of a multicomponent therapy to design efficient treatment.

Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.

  • G. KlementPing Huang R. Kerbel
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002
It is concluded that vascular-targeting protocols involving frequent administration of very low doses of certain chemotherapeutic drugs can provide a stable and safe way to circumvent multidrug resistance in established orthotopically growing tumors, as long as these are used in combination with a second anti-VEGFR-2 blocking antibodies.

Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.

It is concluded that low-dose CP results in immunological effects appealing for oncolytic virotherapy, and the best progression-free and overall survival was seen in the oral + intravenous group.

Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy.

It is found that infection of tumor-bearing mice with VV followed by infection with SFV or vice versa leads to enhanced antitumor effects against murine ovarian surface epithelial carcinoma (MOSEC) tumors and enhanced tumor killing in vitro through a combination of viral oncolysis and antigen-specific immunity.

Mechanisms of endocrine resistance in breast cancer.

The need to better identify a priori the patients whose tumors are most likely to benefit from new treatment combinations targeting both ER and growth factor receptor signaling to block the crosstalk between these pathways and eliminate escape routes is highlighted.